0001144204-11-051233.txt : 20110902 0001144204-11-051233.hdr.sgml : 20110902 20110902170035 ACCESSION NUMBER: 0001144204-11-051233 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20110902 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20110902 DATE AS OF CHANGE: 20110902 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ALLIED HEALTHCARE PRODUCTS INC CENTRAL INDEX KEY: 0000874710 STANDARD INDUSTRIAL CLASSIFICATION: ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842] IRS NUMBER: 231370721 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-19266 FILM NUMBER: 111074112 BUSINESS ADDRESS: STREET 1: 1720 SUBLETTE AVE CITY: ST LOUIS STATE: MO ZIP: 63110 BUSINESS PHONE: 3147712400 MAIL ADDRESS: STREET 1: 1720 SUBLETTE AVENUE CITY: ST LOUIS STATE: MO ZIP: 63110 8-K 1 v234083_8k.htm FORM 8-K

 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
FORM 8-K
 
CURRENT REPORT
 
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported) 
September 2, 2011
 
ALLIED HEALTHCARE PRODUCTS, INC.
 
(Exact name of registrant as specified in its charter)
 
Delaware
0-19266
25-1370721
(State or Other Jurisdiction
of Incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)

1720 Sublette Avenue, St. Louis, Missouri
(Address of principal executive offices)
63110
(Zip Code)

Registrant’s telephone number, including area code 
(314) 771-2400 
  
Not applicable 
(Former name or former address, if changed since last report) 

 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
o    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 

 

Item 2.02 Results of Operation and Financial Condition.


On September 2, 2011, Allied Healthcare Products, Inc. (the “Company”) issued a press release setting forth results for the fourth quarter and year ended June 30, 2011.  The press release is attached hereto as Exhibit 99.1 and incorporated herein by this reference.  The press release and the information included in this Item 2.02 shall not be deemed “filed” with the Commission.


Item 9.01 Financial Statements and Exhibits.

(a)           Not applicable.
(b)           Not applicable.
(c)           Not applicable.
(d)           Exhibits.                      
 
Exhibit
Number
Description
 
 
99.1
Press Release dated September 2, 2011
 

 
 
 

 

 
 
SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
 
 
ALLIED HEALTHCARE PRODUCTS, INC.
 
       
Date:  September 2, 2011    
By:
/s/  Daniel C. Dunn  
    Daniel C. Dunn  
    Chief Financial Officer  
       

 
 
 

 
EX-99.1 2 v234083_ex99-1.htm EXHIBIT 99.1

Exhibit 99.1
 

Contact: 
Daniel C. Dunn
Chief Financial Officer
314/771-2400




Allied Healthcare Reports Profitable Quarter and Year
Despite Lingering Effects of Recession


ST. LOUIS, September 2, 2011 – Allied Healthcare Products, Inc., (NASDAQ: AHPI) reported a profitable fourth quarter and fiscal year despite sluggish sales to hospitals and government entities still suffering from recession-driven budget cuts.
 
Allied announced net income of about $204,000, or 3 cents per basic and diluted share, for the 2011 fiscal year compared to a loss of about $600,000, or a negative 7 cents per share, for the previous year.
 
For the quarter, Allied increased net income to about $115,000, or 1 cent per basic and diluted share, from about $86,000, or 1 cent per share, for the previous year.
 
Allied sales for the fiscal year ended June 30, 2011, increased by about $750,000, or nearly 2 percent, to about $46.8 million. Sales for the fourth quarter increased by almost $434,000, or 3.5 percent, to about $12.1 million compared to the previous year’s fourth quarter.
 
Allied reduced selling, general and administrative (SG&A) expenses in the 2011 fiscal year by more than 10 percent, from about $11.9 million to $10.6 million.  Selling, general and administrative expenses in the prior year were affected by a non-cash charge of $609,000 for the grant of stock options.
 
“Domestic sales to hospitals and emergency markets increased modestly in this fiscal year,” said Earl Refsland, Allied president and chief executive officer. “But both markets remain significantly below pre-recession levels.” Refsland said that sales in Allied’s international markets also remain well below pre-recession levels.
 
 
 

 
 
“Our cost structure is strong, so Allied is well positioned to take advantage of the markets’ return to more normal demand levels,” Refsland said.
 
Allied ended the 2011 fiscal year with more than $6 million in cash, Refsland said.
 
Allied Healthcare Products manufactures a variety of respiratory products used in the healthcare industry in a range of hospital and alternate care settings including sub-acute facilities, home healthcare and emergency medical care. Allied product lines include respiratory care products, medical gas equipment and emergency medical products. Allied products are marketed to hospitals, hospital equipment dealers, hospital construction contractors, home healthcare dealers and emergency medical products dealers.
 
 “SAFE HARBOR” STATEMENT: Statements contained in this release that are not historical facts or information are “forward-looking statements.”  Words such as “believe,” “expect,” “intend,” “will,” “should,” and other expressions that indicate future events and trends identify such forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause the outcome and future results of operations and financial condition to be materially different than stated or anticipated based on the forward-looking statements. Such risks and uncertainties include both general economic risks and uncertainties, risks and uncertainties affecting the demand for and economic factors affecting the delivery of health care services, and specific matters which relate directly to the Company’s operations and properties as discussed in its periodic filings with the Securities and Exchange Commission. The Company cautions that any forward-looking statement contained in this report reflects only the belief of the Company or its management at the time the statement was made. Although the Company believes such forward-looking statements are based upon reasonable assumptions, such assumptions may ultimately prove inaccurate or incomplete. The Company undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date on which the statement was made.



##

 
 

 

ALLIED HEALTHCARE PRODUCTS, INC.
CONSOLIDATED STATEMENT OF OPERATIONS
(UNAUDITED)
 
      Three months ended,       Twelve months ended,  
   
June 30,
   
June 30,
 
   
2011
   
2010
   
2011
   
2010
 
                         
Net sales
  $ 12,101,826     $ 11,668,246     $ 46,783,436     $ 46,034,248  
Cost of sales
    9,068,116       8,772,006       35,780,657       34,944,714  
Gross profit
    3,033,710       2,896,240       11,002,779       11,089,534  
                                 
                                 
Selling, general and administrative expenses
    2,813,753       2,674,223       10,593,869       11,871,758  
Income (loss) from operations
    219,957       222,017       408,910       (782,224 )
                                 
                                 
Interest income
    (9,041 )     (5,764 )     (32,733 )     (10,168 )
Interest expense
    -       1,505       66       4,269  
Other, net
    10,219       13,599       78,150       117,189  
      1,178       9,340       45,483       111,290  
                                 
Income (loss) before provision for
                         
(benefit from) income taxes
    218,779       212,677       363,427       (893,514 )
                                 
Provision for (benefit from) income taxes
    104,053       126,412       159,019       (293,941 )
Net income (loss)
  $ 114,726     $ 86,265     $ 204,408     $ (599,573 )
                                 
Net income (loss) per share - Basic
  $ 0.01     $ 0.01     $ 0.03     $ (0.07 )
                                 
Net income (loss) per share - Diluted
  $ 0.01     $ 0.01     $ 0.03     $ (0.07 )
                                 
Weighted average common shares outstanding - Basic
    8,124,386       8,093,386       8,107,313       8,066,740  
                                 
Weighted average common shares outstanding - Diluted
    8,136,743       8,112,373       8,124,957       8,066,740  
 
 
 
 

 
 
ALLIED HEALTHCARE PRODUCTS, INC.
CONSOLIDATED BALANCE SHEET
(UNAUDITED)
 
   
June 30, 2011
   
June 30, 2010
 
ASSETS
           
Current assets:
           
Cash and cash equivalents
  $ 6,512,887     $ 5,263,324  
Accounts receivable, net of allowances
               
  of $300,000
    5,366,860       5,418,253  
Inventories, net
    10,553,289       11,155,456  
Income tax receivable
    95,578       877,665  
Other current assets
    213,745       221,840  
    Total current assets
    22,742,359       22,936,538  
Property, plant and equipment, net
    8,660,507       9,661,395  
Other assets, net
    362,480       333,084  
    Total assets
  $ 31,765,346     $ 32,931,017  
                 
LIABILITIES AND STOCKHOLDERS' EQUITY
               
Current liabilities:
               
Accounts payable
  $ 1,644,910     $ 1,950,446  
Other accrued liabilities
    1,645,552       2,241,259  
Deferred income taxes
    512,572       429,699  
Deferred revenue
    688,200       688,200  
    Total current liabilities
    4,491,234       5,309,604  
                 
Deferred revenue
    114,700       802,900  
                 
Commitments and contingencies
               
                 
Stockholders' equity:
               
Preferred stock; $0.01 par value; 1,500,000 shares
               
  authorized; no shares issued and outstanding
    -       -  
Series A preferred stock; $0.01 par value; 200,000 shares
               
  authorized; no shares issued and outstanding
    -       -  
Common stock; $0.01 par value; 30,000,000 shares
               
  authorized; 10,427,878 and 10,396,878  shares issued
               
  at June 30, 2011 and June 30, 2010, respectively;
               
  8,124,386 and 8,093,386 shares outstanding at
               
  June 30, 2011 and June 30, 2010, respectively
    104,279       103,969  
Additional paid-in capital
    48,499,103       48,362,922  
Accumulated deficit
    (712,542 )     (916,950 )
Less treasury stock, at cost; 2,303,492 shares at
               
   June 30, 2011 and June 30, 2010, respectively
    (20,731,428 )     (20,731,428 )
    Total stockholders' equity
    27,159,412       26,818,513  
    Total liabilities and stockholders' equity
  $ 31,765,346     $ 32,931,017  
 
 
 

 
GRAPHIC 3 logo.jpg GRAPHIC begin 644 logo.jpg M_]C_X``02D9)1@`!`@$`2`!(``#_X12717AI9@``34T`*@````@`!P$2``,` M```!``$```$:``4````!````8@$;``4````!````:@$H``,````!``(```$Q M``(````<````<@$R``(````4````CH=I``0````!````I````-``"OR````G M$``*_(```"<0061O8F4@4&AO=&]S:&]P($-3,R!7:6YD;W=S`#(P,3$Z,#DZ M,#$@,3@Z-#DZ-3@``````Z`!``,````!``$``*`"``0````!````R*`#``0` M```!````9@`````````&`0,``P````$`!@```1H`!0````$```$>`1L`!0`` M``$```$F`2@``P````$``@```@$`!`````$```$N`@(`!`````$``!-A```` M`````$@````!````2`````'_V/_@`!!*1DE&``$"``!(`$@``/_M``Q!9&]B M95]#30`!_^X`#D%D;V)E`&2``````?_;`(0`#`@("`D(#`D)#!$+"@L1%0\, M#`\5&!,3%1,3&!$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P, M#`$-"PL-#@T0#@X0%`X.#A04#@X.#A01#`P,#`P1$0P,#`P,#!$,#`P,#`P, M#`P,#`P,#`P,#`P,#`P,#`P,#`P,_\``$0@`4@"@`P$B``(1`0,1`?_=``0` M"O_$`3\```$%`0$!`0$!``````````,``0($!08'"`D*"P$``04!`0$!`0$` M`````````0`"`P0%!@<("0H+$``!!`$#`@0"!0<&"`4###,!``(1`P0A$C$% M05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U%J*R@R9$DU1D M1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F M]C='5V=WAY>GM\?7Y_<1``("`0($!`,$!08'!P8%-0$``A$#(3$2!$%187$B M$P4R@9$4H;%"(\%2T?`S)&+A7U5F9VAI:FML;6YO8G-T=7 M9W>'EZ>WQ__:``P#`0`"$0,1`#\`]522224I))))2E0PNN=+S\_,Z=B7BS*Z M<6MRJP"-I?.WW.&RSZ'O]/Z"MY%]6-CVY-[@RFECK+'G@-:-[W?YH7BO^+WK M631_C`-V:#2[K?J>JU\C7(_7\9P!_P!*[TO1_D7)*?;DDEE=;^LW1NA5SGWQ M:X;J\=GNMG_`-;Q:K;J_P!] ML]5M&X9>675X1,,L_1%CG9?4'5.=Z=S7Y%']1-XB?E' MU+8/+PQ_S^3A/^;Q_K,G^%^A![K(_P`9'2'6_9^E8V3U6_\`-;160#_G_IO_ M``!0_;?^,+,A^%T2C$J=_P!RK-SO\WU,=[?^V5>^H&7]N^JF%G.HHQK,CU'/ MKQJQ57+;;:F[:F?R*TW4OK[]7NF=2/3LBRQUE9#;[:V;JZR==MCIWNV_G^BR MU`C]Z1^FB<9C(UAY?C(%^LRRRK^['@@YN5UG_&)TNEV;G=/Q,C$I&^]M+CN: MP?2=_..=[?W_`$KMBZGI/4J>J]-Q^HT`MKR6!X:[D'AS#_5>%D_6&^SK`;]7 MNEV2[,:U^?E,U91B.[[_`*+K\UH]+&J_/K]6W^:_2+N?7'ZN=!L%/5 M,QM-Y;O%+6N>\@SM]E37[=VW\];2Q?K3]6^D==Z;>S.QF67MJ?Z&3$6UN`+F M.KN'OVML]_I_S;_\(DI#]5?KGT[ZTNS/L%-U3,(L!=<&MW>IOVEC6/L_T7YR MZ!>6_P"(XS7UD=YQC]XR%ZDDI__0]522224I))))3SOU\NM'U=LP,=XKRNKV MU=.QR1()R7BJT'_T%]=>??XT^F.Z']9.E]7ZE_5*A]E]K6EV26^X3!>*J[/95Z<^G;DY'Z/\` MZ%R;&^H&1AXEW5NH5?M[K&CV8#[=E3G2/Y_)NEV18UGO_2_H?\%_PJL_XI,K M%ROJRY[*F5Y==[Z\I[0`YY'Z6E[_`,[:VJ[TV?U%VZ`CK9U7SYD1!Q\N#CAU MF?Y[)_>E^C_@/D_U5^N7UHZG]>L+IG42,'&K]:M_3*J_28S938YC'L?NN]KJ MV.][_P#BUU?^-1C'?4;J#G-!-;J',)$D'UZ6;F?NNVOS>^G_`$:O?XNLS&P/\7.%FY3_`$\?';DV6O@N MAK;\ASG;*PY[O[+5S+_KX?K/]>NBX^&UU72L7)FMK_I6V%KV?:+&?19L:[90 MS_C'_P"%].L$6RX.8R89&6,T2*/5]+Z3TG#Z3AMQ,4.+6@;[;#NL>0`SU+K/ MSW;&M9_P;/T=?Z-74#-S,7`Q+7W%IVN=55B[O38WZ/N]3_CD6,DDDDV2]LDN.Z5]<^I8W76? M5SZV8U6'GWP[WV?HO2J_PG8I(4@YG]$O_P"+ M?_U)7,9_^,/"^WOZ5T'#OZ]U"O\`G&XT"ED':[U!]7\+[3E'?:^6X^.T^^QP[-_= MK9_A;?\`!_U_3K0OK/\`6?"^KV%ZMWZ7)LD8^,#!>1^<[]REG^$L7&8W2\S, MQA9'UVZI=]8.L.:W##_2--1(+_3&F,UWTJZ*]WZ6 MS^TU^QC?H[)]JSOJ/@.P/JITVFR M3:^D7VD\[[R1?C.+75C_K5ESG_`/%+V%>)_683W-5 M_P"BS_\`/?\`:FKVOG4(L+Y.3'^//^V/QP5U_P#C/$_47J?PI_\`/]"X^X1_ MCR']=A_]DFKL?\9W_B&ZI\*?_/\`0DI'_BK,_4;I_D;_`/S_`'+D^N8F+B?X MX>G?9JFTBY]-MH8(!L=O:^S:/SG[??\`YZZO_%3_`.(?`_K7_P#GZUG_I<>M:U/U_Z5AX]>+B]%ZMZ-#6U5,KQ-`Q@V,:W?:WZ+6KE_KUD"O_ M`!J]%LN@5TG#$G@-]=[G._LN>Y>M)*?'/K_U?J?UH?T]_3>A]3QGX#K'-OLH M>'R_T]NST0_Z+JM^[>NG_P`8/UHR\'ZDXI`=B]2ZQ76QU9]EE;75B[-]KOHO M9/V9W^C]9=XO(O\`'?:\]0Z723[&46O:/-[F-?\`^>F)*>X_Q??5_&Z)]6<1 MK&`9696S(R[(]SGV#>UCOY-#'^DS_P!2/6KU[I&-UKI&5TW)8',OK<&DC5KX M_16L_EU/]ZN8X:,>H-,M#&P?*$1)3Y3_`(C3[^M?#%_]V5ZLO)_\1^F1UAO\ MBC\#>O6$E/\`_]+U59/UD^L>%]7\`Y.1^DN?+<;&!AUCQ_U%3/\`#6_X/_C/ M3K?=ZAGXO3<*[.RW[**&[GN[^#6M_>>]WL9_+7`="Z9E_77K5G7^KLV],I=L MQ\7AIJLM%#6L MAWZ3=LLW>X-9Z:Y?IW1OK=U'ZY8W7/K#51CXG3Z;6X=%%F\-?8/2.[]Y[V/] M]G_!5(@4LSYY996=(C2$!\L(_NA[8````0!H`$Z22+$^7_X[.E!V/T[J[&B6 M/=B7.[D/'K8_]ECJ[_\`MQ=G]1NJ#JOU4Z;EEVZP4BFXDR?4I_5['._KNK]3 M^VI?7+H+_K!]7,OIE):W(L#7T.?H`]CFV-DP[;OV^G_;7(_5/ZK_`.,;ZKMM MHQ'=.NQ+W^H^FY]D!\!KK*GU5->Q[V,8WW;TE.=EG;_CP:?^$K'WX;0NT_QE M"?J1U3^I7_Y]J6#UOZD_6J[Z[N^M'27X3=IJ=4S)=89+*FX]@L975]'Z?T;% MO]6Z3]8^N_5'-Z7U#['3U/)AK'4NL-&UKZ[`YQLK-S'>Q_YMB2FI_BG,_4G$ M\K+_`/SZ]_TG>E74[W?Z5O\`UQ5OKK]1/K%UGZS8W7.CY6-C.Q:JA6ZYSP]MM3[+ M6O#647UN;[V?324X7^.KIEU?4^G]88#Z=M1QG.;^;96YU]L;<[9_Q"[_ M`.IOUFQ_K)T2G+:]OVRMHKSJ1H66@>X[/]%='JT_R/Y?J(3>A=3ZWT*_I7UQ M&+PLGBYC]K?='NK;;!TK#LSNH7MQ\:H2ZQY_Z+&CW66._ M,K9[WKS3_&K2[K/U=Z/]9J*7U500^M\;VUY(:_'LLVES&_S?_@ZO]"_Q;]6S M,RKJ/UVSG=1]#6C!-C[63I_/OLAFSV_T>CV6_P"$M_P2[WJ/3L3J>!=T_-K% MN-D,-=C#X'NW]U[/IUO_`#'I*<3_`!?]?HZW]6L1[7@Y6)6W&RV3+@^L;!8[ M_CV-];_U6ND7D9_Q<_7?ZN=5=E_5;+;;6Z6LLWM8_8?\'ET7C[/=M_M_Z7]$ MNHQ/JU]=^JU&KZT=;]+$=]/#ZVPC(WZ3&.H3!=G3ZMS-P'%BC')$8XQLQUX_=E_.>ETW] M8P_MPP,?=E90RD!PI!G])EV2VJCZ/\VY_VBS_``5-BRO\8/4,[IOU5RLS M`M=3DUOH#'L(!]UU3'-EP=]-KMJW,/"P\#';BX5+,>AGT:ZP&CXZ?G._.>C$ M`B")'@4\>+5EP_H@UX[E\IZ[]:/K,S,SZ\FU_3',ZAATG%KR:PVNNS%OL>UG M4'T/JK;>YE=_J/H_1*]B_6_-=]9\:YF7??T.JZGI;W"LV8UCWU19EV]3:VNC M[0SJ#Z6^VJOU:/TWZ.M>D%K3R`>Z6UH$`"/!):^48OU@ZAU7ZN]`]'K>2SJ3 MNH5=/ZH*B`X,R[*4#P\TE/EU/ULR\;IW4\[+ZIDN^LU MC;\?]A!I]+'M==7C8;L:OTG-WT-L99_.6?:O^,KL5#-^LW7V].IZ>,OJ'V[` MRK]/]6J7L&ULDP)/)^"4#E)3YM]7^N=0 MR_KQ3C9O57Y+/L^,ZIM5QJQ[GOP_5R;:L+[,?M+'W?I/YS!^SV?]L5DZMD?6 MV[ZZ]49TO*OKP^FC'LNFQHQZJ7X[[<@'#QU?K7,M/[.R7X];=M67 M9C^GZ=EGYGI_I/TOO-T_J'4+NJX&#]8>J=1Z5><7I[.F44[_`-:?=6UO4+,U MSJKO4N;?[7NR'5_9O^MKTY))3Y'F9/4>G=*S++NO9_LZGE8K:[KKFONIP@]M M56+U"FC(9AYESG_X3]#FV?\`$+L>O_6;J?2>C].RL7&_2Y./;9;7EM>ZRMU6 M+9F,KN](U?I?6K;5>NK224\)5]>NMV=4KPLO#KZ37]J;BV693+;)N%>*ZSI] M;L5SJ_7R+```````$`````#A"24T$&@`` M```#/0````8``````````````&8```#(````!`!L`&\`9P!O`````0`````` M```````````````````!``````````````#(````9@`````````````````` M```!`````````````````````````!`````!````````;G5L;`````(````& M8F]U;F1S3V)J8P````$```````!28W0Q````!`````!4;W`@;&]N9P`````` M````3&5F=&QO;F<``````````$)T;VUL;VYG````9@````!29VAT;&]N9P`` M`,@````&7!E`````$YO;F4````)=&]P3W5T```)G````380`8``'_V/_@`!!*1DE&``$"``!(`$@``/_M``Q!9&]B95]# M30`!_^X`#D%D;V)E`&2``````?_;`(0`#`@("`D(#`D)#!$+"@L1%0\,#`\5 M&!,3%1,3&!$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`$- M"PL-#@T0#@X0%`X.#A04#@X.#A01#`P,#`P1$0P,#`P,#!$,#`P,#`P,#`P, M#`P,#`P,#`P,#`P,#`P,#`P,_\``$0@`4@"@`P$B``(1`0,1`?_=``0`"O_$ M`3\```$%`0$!`0$!``````````,``0($!08'"`D*"P$``04!`0$!`0$````` M`````0`"`P0%!@<("0H+$``!!`$#`@0"!0<&"`4###,!``(1`P0A$C$%05%A M$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U%J*R@R9$DU1D1<*C M=#87TE7B9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]C=' M5V=WAY>GM\?7Y_<1``("`0($!`,$!08'!P8%-0$``A$#(3$2!$%187$B$P4R M@9$4H;%"(\%2T?`S)&+A7U5F9VAI:FML;6YO8G-T=79W>' MEZ>WQ__:``P#`0`"$0,1`#\`]522224I))))2E0PNN=+S\_,Z=B7BS*Z<6MR MJP"-I?.WW.&RSZ'O]/Z"MY%]6-CVY-[@RFECK+'G@-:-[W?YH7BO^+WK631_ MC`-V:#2[K?J>JU\C7(_7\9P!_P!*[TO1_D7)*?;DDEE=;^LW1NA5SGWQ:X;J M\=GNMG_`-;Q:K;J_P!]L]5M&X9>675X1,,L_1%CG9?4'5.=Z=S7Y%']1-XB?E'U+8/ M+PQ_S^3A/^;Q_K,G^%^A![K(_P`9'2'6_9^E8V3U6_\`-;160#_G_IO_``!0 M_;?^,+,A^%T2C$J=_P!RK-SO\WU,=[?^V5>^H&7]N^JF%G.HHQK,CU'/KQJQ M57+;;:F[:F?R*TW4OK[]7NF=2/3LBRQUE9#;[:V;JZR==MCIWNV_G^BRU`C] MZ1^FB<9C(UAY?C(%^LRRRK^['@@YN5UG_&)TNEV;G=/Q,C$I&^]M+CN:P?2= M_..=[?W_`$KMBZGI/4J>J]-Q^HT`MKR6!X:[D'AS#_5>%D_6&^SK`;]7NEV2 M[,:U^?E,U91B.[[_`*+K\UH]+&J_/K]6W^:_2+N?7'ZN=!L%/5,QM- MY;O%+6N>\@SM]E37[=VW\];2Q?K3]6^D==Z;>S.QF67MJ?Z&3$6UN`+F.KN' MOVML]_I_S;_\(DI#]5?KGT[ZTNS/L%-U3,(L!=<&MW>IOVEC6/L_T7YRZ!>6 M_P"(XS7UD=YQC]XR%ZDDI__0]522224I))))3SOU\NM'U=LP,=XKRNKVU=.Q MR1()R7BJT'_T%]=>??XT^F.Z']9.E]7ZE_5*A]E]K6EV26^X3!>*J[/95Z<^G;DY'Z/\`Z%R; M&^H&1AXEW5NH5?M[K&CV8#[=E3G2/Y_)NEV18UGO_2_H?\%_PJL_XI,K%ROJ MRY[*F5Y==[Z\I[0`YY'Z6E[_`,[:VJ[TV?U%VZ`CK9U7SYD1!Q\N#CAUF?Y[ M)_>E^C_@/D_U5^N7UHZG]>L+IG42,'&K]:M_3*J_28S938YC'L?NN]KJV.][ M_P#BUU?^-1C'?4;J#G-!-;J',)$D'UZ6;F?NNVOS>^G_`$:O?XNLS&P/\7.%FY3_`$\?';DV6O@NAK;\ MASG;*PY[O[+5S+_KX?K/]>NBX^&UU72L7)FMK_I6V%KV?:+&?19L:[90S_C' M_P"%].L$6RX.8R89&6,T2*/5]+Z3TG#Z3AMQ,4.+6@;[;#NL>0`SU+K/SW;& MM9_P;/T=?Z-74#-S,7`Q+7W%IVN=55B[O38WZ/N]3_CD6,DDDDV2]LDN.Z5]<^I8W76?5SZV M8U6'GWP[WV?HO2J_PG8I(4@YG]$O_P"+?_U) M7,9_^,/"^WOZ5T'#OZ]U"O\`G&XT"ED':[U!]7\+[3E'?:^6X^.T^^QP[-_=K9_A M;?\`!_U_3K0OK/\`6?"^KV%ZMWZ7)LD8^,#!>1^<[]REG^$L7&8W2\S,QA9'UVZI=]8.L.:W##_2--1(+_3&F,UWTJZ*]WZ6S^TU^QC?H[)]JSOJ/@.P/JITVFR3:^D M7VD\[[R1?C.+75C_K5ESG_`/%+V%>)_683W-5_P"B MS_\`/?\`:FKVOG4(L+Y.3'^//^V/QP5U_P#C/$_47J?PI_\`/]"X^X1_CR'] M=A_]DFKL?\9W_B&ZI\*?_/\`0DI'_BK,_4;I_D;_`/S_`'+D^N8F+B?XX>G? M9JFTBY]-MH8(!L=O:^S:/SG[??\`YZZO_%3_`.(?`_K7_P#GZUG_I<>M:U/U_Z5AX]>+B]%ZMZ-#6U5,KQ-`Q@V,:W?:WZ+6KE_KUD"O_`!J] M%LN@5TG#$G@-]=[G._LN>Y>M)*?'/K_U?J?UH?T]_3>A]3QGX#K'-OLH>'R_ MT]NST0_Z+JM^[>NG_P`8/UHR\'ZDXI`=B]2ZQ76QU9]EE;75B[-]KOHO9/V9 MW^C]9=XO(O\`'?:\]0Z723[&46O:/-[F-?\`^>F)*>X_Q??5_&Z)]6<1K&`9 M696S(R[(]SGV#>UCOY-#'^DS_P!2/6KU[I&-UKI&5TW)8',OK<&DC5KX_16L M_EU/]ZN8X:,>H-,M#&P?*$1)3Y3_`(C3[^M?#%_]V5ZLO)_\1^F1UAO\BC\# M>O6$E/\`_]+U59/UD^L>%]7\`Y.1^DN?+<;&!AUCQ_U%3/\`#6_X/_C/3K?= MZAGXO3<*[.RW[**&[GN[^#6M_>>]WL9_+7`="Z9E_77K5G7^KLV],I=LQ\7AIJLM%#6LAWZ3 M=LLW>X-9Z:Y?IW1OK=U'ZY8W7/K#51CXG3Z;6X=%%F\-?8/2.[]Y[V/]]G_! M5(@4LSYY996=(C2$!\L(_NA[8````0!H`$Z22+$^7_X[.E!V/T[J[&B6/=B7 M.[D/'K8_]ECJ[_\`MQ=G]1NJ#JOU4Z;EEVZP4BFXDR?4I_5['._KNK]3^VI? M7+H+_K!]7,OIE):W(L#7T.?H`]CFV-DP[;OV^G_;7(_5/ZK_`.,;ZKMMHQ'= M.NQ+W^H^FY]D!\!KK*GU5->Q[V,8WW;TE.=EG;_CP:?^$K'WX;0NT_QE"?J1 MU3^I7_Y]J6#UOZD_6J[Z[N^M'27X3=IJ=4S)=89+*FX]@L975]'Z?T;%O]6Z M3]8^N_5'-Z7U#['3U/)AK'4NL-&UKZ[`YQLK-S'>Q_YMB2FI_BG,_4G$\K+_ M`/SZ]_TG>E74[W?Z5O\`UQ5OKK]1/K%UGZS8W7.CY6-C.Q:JA6ZYSP]MM3[+6O#6 M47UN;[V?324X7^.KIEU?4^G]88#Z=M1QG.;^;96YU]L;<[9_Q"[_`.IO MUFQ_K)T2G+:]OVRMHKSJ1H66@>X[/]%='JT_R/Y?J(3>A=3ZWT*_I7UQ&+PLGBYC]K?='NK;;!TK#LSNH7MQ\:H2ZQY_Z+&CW66._,K9[ MWKS3_&K2[K/U=Z/]9J*7U500^M\;VUY(:_'LLVES&_S?_@ZO]"_Q;]6S,RKJ M/UVSG=1]#6C!-C[63I_/OLAFSV_T>CV6_P"$M_P2[WJ/3L3J>!=T_-K%N-D, M-=C#X'NW]U[/IUO_`#'I*<3_`!?]?HZW]6L1[7@Y6)6W&RV3+@^L;!8[_CV- M];_U6ND7D9_Q<_7?ZN=5=E_5;+;;6Z6LLWM8_8?\'ET7C[/=M_M_Z7]$NHQ/ MJU]=^JU&KZT=;]+$=]/#ZVPC(WZ3&.H3!=G3ZMS-P'%BC')$8XQLQUX_=E_.>ETW]8P_M MPP,?=E90RD!PI!G])EV2VJCZ/\VY_VBS_``5-BRO\8/4,[IOU5RLS`M=3 MDUOH#'L(!]UU3'-EP=]-KMJW,/"P\#';BX5+,>AGT:ZP&CXZ?G._.>C$`B") M'@4\>+5EP_H@UX[E\IZ[]:/K,S,SZ\FU_3',ZAATG%KR:PVNNS%OL>UG4'T/ MJK;>YE=_J/H_1*]B_6_-=]9\:YF7??T.JZGI;W"LV8UCWU19EV]3:VNC[0SJ M#Z6^VJOU:/TWZ.M>D%K3R`>Z6UH$`"/!):^48OU@ZAU7ZN]`]'K>2SJ3NH5= M/ZH*B`X,R[*4#P\TE/EU/ULR\;IW4\[+ZIDN^LUC;\? M]A!I]+'M==7C8;L:OTG-WT-L99_.6?:O^,KL5#-^LW7V].IZ>,OJ'V[`RK]/]6J7L&ULDP)/)^"4#E)3YM]7^N=0R_KQ M3C9O57Y+/L^,ZIM5QJQ[GOP_5R;:L+[,?M+'W?I/YS!^SV?]L5DZMD?6V[ZZ M]49TO*OKP^FC'LNFQHQZJ7X[[<@'#QU?K7,M/[.R7X];=M679C^G MZ=EGYGI_I/TOO-T_J'4+NJX&#]8>J=1Z5><7I[.F44[_`-:?=6UO4+,USJKO M4N;?[7NR'5_9O^MKTY))3Y'F9/4>G=*S++NO9_LZGE8K:[KKFONIP@]M56+U M"FC(9AYESG_X3]#FV?\`$+L>O_6;J?2>C].RL7&_2Y./;9;7EM>ZRMU6+9F, MKN](U?I?6K;5>NK224\)5]>NMV=4KPLO#KZ37]J;BV693+;)N%>*ZSI];L5S MJ_7R+FMC M.60B/SX@/'@Z>&UP;65T82!X;6QN#IX M;7!T:STB061O8F4@6$U0($-O&UL;G,Z&UL;G,Z=&EF9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]T M:69F+S$N,"\B('AM;&YS.F5X:68](FAT='`Z+R]N&%P.DUO9&EF>41A=&4] M(C(P,3$M,#DM,#%4,3@Z-#DZ-3@M,#0Z,#`B('AA<#I-971A9&%T841A=&4] M(C(P,3$M,#DM,#%4,3@Z-#DZ-3@M,#0Z,#`B('AA<$U-.D1O8W5M96YT240] M(G5U:60Z-48W.#%#.35%0T0T13`Q,3DX,3,Y-#&EF.DYA=&EV941I9V5S=#TB M,S8X-C0L-#`Y-C`L-#`Y-C$L,S`&,`:`!M`'(` M=P!\`($`A@"+`)``E0":`)\`I`"I`*X`L@"W`+P`P0#&`,L`T`#5`-L`X`#E M`.L`\`#V`/L!`0$'`0T!$P$9`1\!)0$K`3(!.`$^`44!3`%2`5D!8`%G`6X! M=0%\`8,!BP&2`9H!H0&I`;$!N0'!`$!Z0'R`?H"`P(,`A0"'0(F M`B\".`)!`DL"5`)=`F<"<0)Z`H0"C@*8`J("K`*V`L$"RP+5`N`"ZP+U`P`# M"P,6`R$#+0,X`T,#3P-:`V8#<@-^`XH#E@.B`ZX#N@/'`],#X`/L`_D$!@03 M!"`$+00[!$@$501C!'$$?@2,!)H$J`2V!,0$TP3A!/`$_@4-!1P%*P4Z!4D% M6`5G!7<%A@66!:8%M07%!=4%Y07V!@8&%@8G!C<&2`99!FH&>P:,!IT&KP;` M!M$&XP;U!P<'&09!ZP'OP?2!^4'^`@+"!\(,@A&"%H( M;@B"")8(J@B^"-((YPC["1`))0DZ"4\)9`EY"8\)I`FZ"<\)Y0G["A$*)PH] M"E0*:@J!"I@*K@K%"MP*\PL+"R(+.0M1"VD+@`N8"[`+R`OA"_D,$@PJ#$,, M7`QU#(X,IPS`#-D,\PT-#28-0`U:#70-C@VI#<,-W@WX#A,.+@Y)#F0.?PZ; M#K8.T@[N#PD/)0]!#UX/>@^6#[,/SP_L$`D0)A!#$&$0?A";$+D0UQ#U$1,1 M,1%/$6T1C!&J$)%ZX7TA?W&!L80!AE&(H8KQC5&/H9(!E%&6L9D1FW&=T:!!HJ M&E$:=QJ>&L4:[!L4&SL;8QN*&[(;VAP"'"H<4AQ['*,0!YJ'I0>OA[I'Q,?/A]I'Y0?OQ_J(!4@02!L()@@Q"#P(1PA2"%U M(:$ASB'[(B--@U$S5--8Y",$)R0K5"]T,Z0WU# MP$0#1$=$BD3.11)%546:1=Y&(D9G1JM&\$25^!8+UA]6,M9&EEI6;A:!UI66J9:]5M%6Y5;Y5PU7(9O5\/7V%?LV`%8%=@JF#\84]AHF'U8DEBG&+P8T-CEV/K9$!DE&3I M93UEDF7G9CUFDF;H9SUGDV?I:#]HEFCL:4-IFFGQ:DAJGVKW:T]KIVO_;%=L MKVT(;6!MN6X2;FMNQ&\>;WAOT7`K<(9PX'$Z<95Q\')+%V/G:;=OAW5G>S>!%X;GC,>2IYB7GG>D9ZI7L$>V-[PGPA?(%\ MX7U!?:%^`7YB?L)_(W^$?^6`1X"H@0J!:X'-@C""DH+T@U>#NH0=A("$XX5' MA:N&#H9RAM>'.X>?B`2(:8C.B3.)F8G^BF2*RHLPBY:+_(QCC,J-,8V8C?^. M9H[.CS:/GI`&D&Z0UI$_D:B2$9)ZDN.339.VE""4BI3TE5^5R98TEI^7"I=U ME^"83)BXF229D)G\FFB:U9M"FZ^<')R)G/>=9)W2GD">KI\=GXN?^J!IH-BA M1Z&VHB:BEJ,&HW:CYJ16I,>E.*6IIAJFBZ;]IVZGX*A2J,2I-ZFIJARJCZL" MJW6KZ:QK_U MP'#`[,%GP>/"7\+;PUC#U,11Q,[%2\7(QD;&P\=!Q[_(/%$XIZ#+HO.E&Z=#J6^KEZW#K^^R&[1'MG.XH M[K3O0._,\%CPY?%R\?_RC/,9\Z?T-/3"]5#UWO9M]OOWBO@9^*CY./G'^E?Z MY_MW_`?\F/TI_;K^2_[<_VW____N``Y!9&]B90!D0`````'_VP"$``0#`P,# M`P0#`P0&!`,$!@<%!`0%!P@&!@<&!@@*"`D)"0D("@H,#`P,#`H,#`P,#`P, M#`P,#`P,#`P,#`P,#`P!!`4%"`<(#PH*#Q0.#@X4%`X.#@X4$0P,#`P,$1$, M#`P,#`P1#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#/_``!$(`&8`R`,! M$0`"$0$#$0'_W0`$`!G_Q`&B````!P$!`0$!```````````$!0,"!@$`!P@) M"@L!``("`P$!`0$!``````````$``@,$!08'"`D*"Q```@$#`P($`@8'`P0" M!@)S`0(#$00`!2$2,4%1!A-A(G&!%#*1H0<5L4(CP5+1X3,68O`D'EZ>WQ]?G]SA(6&AXB)BHN,C8 MZ/@I.4E9:7F)F:FYR=GI^2HZ2EIJ>HJ:JKK*VNKZ$0`"`@$"`P4%!`4&!`@# M`VT!``(1`P0A$C%!!5$382(&<8&1,J&Q\!3!T>$C0A528G+Q,R0T0X(6DE,E MHF.RP@=STC7B1(,75),("0H8&28V11HG9'15-_*CL\,H*=/C\X24I+3$U.3T M976%E:6UQ=7E]4969G:&EJ:VQM;F]D=79W>'EZ>WQ]?G]SA(6&AXB)BHN,C8 MZ/@Y25EI>8F9J;G)V>GY*CI*6FIZBIJJNLK:ZOK_V@`,`P$``A$#$0`_`/?V M*NQ5V*NQ5V*NQ5`W^M:-I<]I:ZGJ-M97.H2>C80W,T<,EQ+M\$2NP+MN-EJ< M51V*NQ5V*NQ5V*I3KOF?RYY8MC>>8M6M-*M@"?4O)XX`:>',BOT97+)&/,N1 MAT^7,:QQ,CY"WCGF3_G+W\F]!:2&ROKK7;A-@NG6[&-C[23&-3\Q7*3G_FQ) M^QZ73^RNNR[R`@/Z1_0+8:__`#EIYVUMJ^2/RJU*_MF_N[B8SN"/&D$#+_R4 MP&>4C8`?.7_$NS'LQIL7]_J8Q/E7Z9?H4+K_`)R:_.[18FU+S!^4EQ!H\7Q3 MR\+R+@G[/R'AAJ1Q'^K^M[=^4/YP^6_P`XM"GU M;0XY;2\LG6'4M-N"IE@=QR4AEV9&`/%AX'89;CF96[5[)R]GY!">X/TR M'5Z)EKIG8J[%78JTS*BEW(5%%68F@`'B<5>9>>?^#\\O+NG:5/QE\C6EO>0LI MKPU"XF6ZK\^,<.*OT3\G>9;/SCY3T3S78$&SUJQM[^*G87$:OQ^@FF*IWBKL M5>-_F-_SDW^5WY=O-8R7YUS7H:AM,TNDQ5QVDEKZ:>XY%A_+F.

Z:GECRM%R^L:LI2**",5J M9M0NN,:D#KZ85LAPSES/^E_7S>J/9/9?9HO4RXY=W_'(_P"^8)Y/\M_D[YK_ M`#.TKR9YZ_,2_P#.WG76IVA;]!!Y]/2549RDNHW!Y2;*=X4XC^;+(88Q')P- M3[6&(X-+C$(]Y_XD;/N#RK^2WY6^3!&=`\KV,5S'2EW-&+FYJ._JS5U/:VKU!_>9)'R^D?(,[```44`'0#PPNJ2+SKYKTCR1Y5U7S3KKA--TV M!YI5-*R-2B1J#U9V(51[Y&4N$6Y>CTL]3FCBASD?P?@\@_YQ7_+W4O+'EG5O M.>NVPL=8\[7(U$:3KOR5YCGN[;3KITE]?3YO0G22 M(U4UH0PJ=U8%3BK\GO\`G(W\B;W\@O.J>7)+\:KI&I6IO](U`QB*5H>;1LDJ M`D!T8;D&C"C;=,5?K-^5+%_RO\E,10G0M,V_Z-(L59?BK__1]_8J[%78J[%7 M8JTS*BEW(5%!+,=@`.I.*ORB_/+R5<^<_(VK?\Y,+ZCCS#YRO[-*D\!HJ`6U MDX!Z?'`RU_RUQ5]=_P#.!7GC_%'Y(1Z!<2^I?>4KV;36!ZBVE/UB`_*CLH_U M<5>N_FA^=WD3\I[0GS#>^OK+ISM=$M*27DH[$K6B+_EN5'A7*9Y0#0W+NNS> MQ]1KI?NQZ>LS](_7\'R1JOYE?GU_SDOJL^@^2;6;2_*Y;A-;63M!;1QGO>7A M"EJC]@=?V8\JX3/ZM_+^%]!Q]G]G=CP$\QXI^?U?YD.GX]2=>7?R]_YQL_)_ M7]*T;\U/-5MYH_,"_N8;6'0;57N+2WN)W$:"2&$,?M,!6(#J\SVC[ M5ZC/<QLW$^FOI;"!(954JO M*`#TY$%?L,O^KQ.^6/&2D9&R;+\XOR3\GW?Y??\`.8'ESR3?7$=W=:#KUQ82 M7,(*QR^E!+1PIK2H(-.V+%^KFNW=WI^B:E?V$/UB^M;6>>VM^OJ2QQLR)_LB M`,!;L,8RR1$C0)%^Y^5-Q^9_YAW'F-O-DWF34%\P&7UOK0N)%X-6O$)7B$'3 MA3C3:F8)PP(OK_.Z_-^@,?9FFCB&(0CP5W/NWREIOF/\](?+7FK\P+)]/\EZ M5!;W=IY?F7@VJZNJ#E>W$?:W1J_5XC]O^\?X>(R^$92HRZ?BWR359,79WB8L M!XLDB8F8_P`GC_F1_IG^.73D]YS(>4=BKL5=BKL5=BK\ZO\`GY/3_%GD4]_T M9?BO_/>/%7V[^3+%_P`H_(K$DDZ#IF[=?]Y8\59QBK__TO?V*NQ5V*NQ5V*O M,?\`G(?SA)Y&_)CSAKMLU-1-@]CIJC=FO+\BUA"CN>4@(^6*L4\P?DQ;?]"I MS?E&R+]9L?+BK&S4VU*UC%USKT%9U._O@)I(%O@+\@_S"_,3\IK7S!#Y5XQW MOFR&WMDB,;3SQ2PNQ26*,5'J$2,B@JWVOLY3,DB@:?0^Q_98RCXVK],>?!R_ MSLG\T>7-]1_E9_SB9K_FR^'G7\ZKNY5KM_K#:.\I>_N"V];J:I,8/\BGGVJF M,]]*>^;YI?E-YB_+35/R=_/W3O( MNK7D6HW6F:SI4JW\`*K-%<3Q31N5;=6*M\0J:-^T<6I^S&*OS"A(B_Y^#EA\ M(/FQUV\7MR/QKBK]/<5>+>8?R]_YQXT[\R-!AUO0[!//?F:6XN-*L@LA6XDM M%]:69X$/I`#^9UHS>)R/".YW`[9U@Q^&,AX>7P_K?4]H````%`-@!DG3MXJ[ M%78J[%78J[%7YU_\_*$;_%'D-R/A.G:@`?$B:*H_'%7VQ^23!OR>\AL#4'0- M-W_Z-8\59YBK_]/W]BKL5=BKL5=BKYR_YR8U_19_-7Y7>0]R=(HO"*N_[7-OA&,;F=_\`2_\`%/J. MA[,TW8^/Q]20GZ=J$P9?*&IV-U/+$K*E MU;2*CNX!WXM&[`#,H"GCNV.W\^O/#]&/^8.O]?O^Y^NUO<0W=O%=6SB2WG19 M8I%W#(XY*1[$'"\RJ8J_*_\`YRX#0?\`.7$KC8M-H#J?DD'],5?JABK\P6!7 M_GX+Q/\`U-P/_!08J^Z?SY_/+2/R)\J1^8]3TF^UB:[=X+&WLT_+$!5J".Y=R0/Y4D_P!7 M%7R=_P`Y4?G_`*#^?@\GZIINF76C:SHUM?6NLZ;=<76.29XBOIRBG-3P;JJ, MO=<5?I3^0KF3\E/R_=NIT#3NGM;H,5>B8J__U/?V*NQ5V*NQ5BGYA?F)Y8_+ M+R[/YD\T70AMDJMM;)1KBYFI410I4?/[GT[AT?8&&SZLTA_G2_XB'XW?<7Y=_EMY4_+#0(_+_E:T$,6SW=V]&N;F M8"ADF>E2?`?97HH&7@4^9:_7YM9E.3(;/=TCY1?"'_/QCR1]0\Z^5_/L$5+? M6[*33+R0=/K-@W-"?^LO\`G$SSP?/GY#>4]0GD]34--@.C7Q)J MWJZP1W-I.I2:"9%DC=&ZJRL""#X'%7Y> M?EAHFD^6/^<[H]`T2W6STBP\PZI!96J?8BC%O.51?!16@'ABKZY_YS;_`#+N M?R^_)6[L-+F:#6O-DZZ+;RQDJZ6\BM)OR MB_)O2-)U?SCIUAYIU(R:EK\125YEN9F(2-S'$W]W&$4"NV*O3]4_YS;_`.<< M-,)"^:GOB.UG8W4`]GY8\S>89[46T@". MUEK$IC/-`:#XW$E/V3BKZ\_YSL_-^[_+[\M+?RAH=R]MY@\YO+;/-$W&2+3( M`IN6!&X+\TB'LSXJFO\`SA5^3^F?EW^4VG>:;BV0^;?.$*:C?7;*/5CLY/BM MK=2=PH0AV`^T[;]%Q5]+8J_+[_GX!^7&B^3OS-TOS/H5LEG%YNLYKG4((@%C M-_:R!9)0HV!D5T+>+5;J<5??7_./YK^2'Y?'_M0Z?_R87%7H^*O_U??V*NQ5 MV*L%_-3\U_*_Y2^77USS!+ZEU+5--TN(CZQ=S`?90'HH_;<_"H]Z`USG7O=M MV9V7EUV7@AR_BETC^.Y\8:=HGG?_`)R1UK5?S1_,*[DTW\N/+T4]QF[#P^%A'%E/XXLGZ(O?/^<) MO+[:;^2L/F.:(PW/FW4+S5Q&S%BEMZGU>W0$]E2(4^>9#Y9J=3DU&0Y,AXI2 MZOHW%QWS?_SG%Y*_Q;^0FJZA!$)+_P`L7$&LP&GQ".-O2GI_SSD8G_5Q5X?_ M`,^XO/7"Z\X?EQ=2"DJPZ[IR%OVEI;W``/B#$VWOBK]`,5?EA_SFN&C_`.8_(WEP,1;6UA>ZB4!V,E MQ*D(/T"(_?BKZR_+_P#)C\H9_(OE>Z?R3H=Q+-I-A(]Q)86TCR,]M&Q=F*$L M6)J3WQ5E$?Y._E-%3T_(V@K3I33;7_JGBJ.L_P`MOR[TZXBO+#REHUM=P,)( M9X=/MDD1U-0RLL8((/0C%7YO_P#/P+7+G4_STCT=F8VVC:-:P11G[(:Z+W#$ M?/DOW8J_2[R?:1V'E+0+&)!'%:Z=9P)&.BK'`B@#Y4Q5.L5?`G_/RN(T_+F8 M*=_TO'R[;BU-,5?5?_..+B3\B/R]85(_0=F/BZ[1@8J]0Q5__];W]BKL58'^ M;/YK^7?RD\L2:]K;>M>2UBTO3$8":ZG`KQ6O11U=^BCWX@USGP^]V_979>37 MYN"&P_BE_-'Z^Y\?_E]^7_GC_G*;SQ/Y\\^3R6_DZWE].:6.J(R(:BRL@>@' M^[).WO(V51C9^]]'[0[0P=BZ<8,`'B5^)S\_+_>O:_\`G+;4;+\OO^<>;GR9 MY4M8[)_,,MIY7T73[<<`%NGK(J@>,:.">Y;,@"GR;+EGED9S-R/,OGYTR\LQ)_EV\ZR$5^4V*OJW_G$_P`ZV_GC\A?*%ZDPEO=, MM1H^H+^TD^G_`+D`CW0(W^RQ5[3BKL5?E5_SGUIMQ8_\Y`7-[(K"+4M(L)X& M/1A$K0-3Y&/%7Z6?EIKUMYH_+SRKYAM'YP:EI5E3[%^-TT55AM[<&J65J3MS8 M;N_7]MM^*Y4(DG[WU'5ZK!V'I1BQ;Y)?:?\`5)_H?>NBZ+I7EW2K31-$M([' M2K&-8;6UA'%$1>@`_63N3NP\K/)YIUZ"E566-?5A#=JA8A3_C+A:GUKBKL5=BK\F?^(*5CO(QZ=Q&0.G&16'RQ5^<_\`SG:/3_YR/Y[BNF:4P/R9AM]V*OU*MB3; M0D]2B]?D,5?F'^8QI_SGU;TZ_P")]$Z?\8K?%7Z@XJ_+]KF&R_Y^"&>YE6&$ M>;2ID=@J@RP\%!)\2P&*OJO_`)S;_*>^_,K\HVU30[=KGS#Y0F;5;:W0%GEM M2G"ZC4`&K<`)`._ITQ5\7?\`.)G_`#D@OY&>8KK2_,0EN/R^U]D;41"I>2SN MD'%;J-.K#C\,JC=EXL*LG$JOTGL?SQ_)S4=)77+7SWH;:8R>IZSW\$1`'7DD MC*ZD?RLO+%7@/FS_`)RAU+\V?/FE?D__`,XZ^K=275U$_F'SJ(V6"UT^&16G M:WYKTX@KZK@`UX19/)>D_F9I4+37GE1GM]65!R/Z,NB# MZA'A%(`3_DNQ[8JPS_G"#_G)?0]'TF+\F_/U^E@L4K-Y4U2Z<+;E)FY-9R.V MR$.2T18\6Y<.O'DJ^^_5B]/UN:^E3EZE1QIXUZ8J_.S_`)^&?F'Y,\T7GD_R MOY2_M8J^L_^<4KJ*[_YQX_+ M]XI!)Z>F+"_$AJ/%(Z%33H13IBKV/%7_T/?%W=VUA:SWU[*L%G;1M-<3R'BB M1Q@LS,3T``K@)IG"!G(1B+)?`OFC5?-'_.6GYO1:!Y?:6W\DZ4S"WE8$1VUB M&"RW7+5;72K!`D:#=G;]J21OVG<_$S>.9`%"GRO5:K)J/\`G)O_`)QA3_G(*7R]?6>MQZ#JNB+<0R7,EN;D36]QP8)0.E.# M*2/]9L5>V2*ZR?#Z;BY:1Y/A`(I7?%7F7YJ?\` M.$9_,C\S]6_,VT\^7&A7VHSP7,$,%D'DMY+>)(U9)A.AJ"G($`4Q5[3^4/Y< M_F!^7\=_;^<_S&O?/EK.L2Z?'J%K'#):F/ES/JAW=^8*BC-MQQ5X=^9O_."& MG?F/^8.O>?F\\7&ES:Y=?7/J<5@DHA;BJT$AG4G=:UH,5>U_DM^5/F[\K+2^ MT[S#^8>H^>-.F2%-.@U.%4:S]+ERX2&25V#@J*%J#CBKQ;\Z/^<#/*7GW6[G MS1Y`U5?*.JWK&6]TTP>OILLS$EI$165H2Q^T%JG@JXJ\GT?_`)]N>;I+]!YA M\ZZ;!IH;]Z]C:S3W#)WXB7TU!^9.*OM/\HOR5\B?DKY?_07DVRXS3<6U+5;B MDE[>2+^U+)0;#]E%`1?V5Q5GMW:6NH6D]C?0IJ? M\YD_F7>:=I>G?E9H+,VI>80)]4$6[FT#\(H!3>LT@W'\J4_:RC(;V?0/9'L^ M,IRU.3ZYO4D9P/3,@[QAN2_M4RN.02.SDY=-DQ1$ICAXN5_5[^'GP M^;QO_G+SSQYK_+_\L]-U[R?>W%EJ9U_3K>4V?'U9H)&?G".0(^.@&6.,^6[CSIK'EKSEYPUN9Y_,GFCZI]:LM*LX$9W7ZD'40R2LJI4<_ MMXJGOE7_`)R"\S>9Y/\`G'#5)?,;V=IK4^L:5YX5Y(XH+JYTN*)`TY8`#ER$ M@^S_`'F*M&X_-:#\^?/GEJ'\U-8OO+_EGRW<>;;"$"$03M:YY8C:Z]"\K)Z-$^+X1LW M(#[&*LQ_)+SEYL\^ZC??F]YV_-N314TW7+ZVN?RWK!'9I8V<;GZNT3.KF3B" MZL%+'@?M&O%5Y_\`E-_SDQYLUWSYJDFJ^<);ZR\\Z7YADTG03S7]`WUEZLU@ MB$KQK)"FQ4G<_%OBK%_R\_.W\X-6\I>=K^P\\:U>P:1Y+EU/69-8>%9[;5Y+ MD)!)II6LIBXTY2';XF#?[KQ5]5_\X@ZUYF\P>2+W5O-.IZ[JE])&61V;X?M<]BN*O0='\Y^>/(^N_E-J6D_F MS=_F'<_F4C1^8_+]S)#-';B:W60SVR1U:#T&8C?O'OMR556(?E7^;7YG:5;? MEAYN/YDWOFO7/.7F.70=<\AZA-'=%;$3-$+F-162(J`&Y&FY'[/(8JF-C^=' MF]OR3\IV\OG2]G\_S?F0NEWT(O#^DY;!9VK`ZUY^D05%".'[/MBK+_RWUC7? MS8\X^9?,?G+\XK_RAK]IYFNO+>F^1+.YBMHEM#R@CB%NY#/*Q)X2A6H\?)N7 M[*K$-(M/S>'EG\W)M._-C4_T]Y?\P_X,T4Z_JL=G;7$)E1FX33?#'>2*.$3\ ME&[=*XJ^B/\`G%_SW#K_`.5&KR1S:W=ZIY:O[ZSU(>9+R/4YTNH$$AABO(55 M985KQ5@*XJ\ND_YS@UO3](NM0U7RK;IZGEW3M6TRZ@:>2T&K:D7,=I[T^QA:^?\`3PNK"9(6 M>XMV`18W+'COR7X.O+%7N6*O_](;_P`Y$2:AY%_YR0TWS]YATZ74O+B-87UB M@^".6.S4*T2N05#)(O*A]OYLQ\EWL^L=@\&I[+E@A(1GZHG_`#NOQ>TZ'_SE M'=^=ZVWY>_ESKFMWY%`\IAMK-&/^_+@EE4?/(^+,\H_:\SF]G(Z8_O\`/"`^ M,I?Z5EUKY"_,+SRPN?S7UQ+/16W_`,&>7'D@M64_LWEY433#^9$,<9_RLF,9 ME]9OR_A_:ZZ6NT^FVTL+E_JN3>7^9#Z8_;)Z?I>E:;HFGV^E:/:16.FVJ".W MM+=%BBC0=E50`,N`IT63)+)(RD22>I2OS=Y*\K>?--AT?S=IL>JZ;!5.=7TJ%!&EL:L?@"J!X^^*K8?RF_ M+FWTSRWH\/EZU33/*%S]=\MVPY\;*Y!+>I'\5:U8GXJXJDVJ_P#./7Y+:WYD MO/-VJ>3+"?S#?K(MY><70RF="DC,B.J&CB.7[:IR)"*W<)Q&*N\J?DC^4?D;51KOE+R;I>DZR MH94OK>W43H'V8([5*U_R<56VWY&_E#9^;?\`'=KY-TR+S;Z[78U-8`)!5O)^AKY9\KZ1:Z3H"1)8^9`WH\:-[E5KTQ5FN*O__3]X:I^A_JX_37U;ZI7;ZY MZ?I\O^>FU<6S'QWZ;OR5K+ZE]73]'>E]4_8^K\?3^CAMBQEQ7ZN:(Q8NQ5V* HNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*O_V3\_ ` end